Poorna Nalabothu, MD
Advanced Heart Failure and Transplant Cardiology · Salt Lake City, UTNPI 1538390869
Payments from drug & device makers
Across 655 payments — averaging $28.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Abbott$2K
- Edwards Lifesciences$2K
- Abiomed$1K
- Cvrx, Inc.$1K
- Pfizer$950
- plus $7K from 30 others
What the payments were for
- Travel & lodging$4,53325%
- Food & beverage$13,88875%
- Education$280%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 170 | $3,773 |
| Abbott | 27 | $2,224 |
| Edwards Lifesciences | 7 | $1,513 |
| Abiomed | 19 | $1,282 |
| Cvrx, Inc. | 6 | $1,254 |
| Pfizer | 68 | $950 |
| Johnson & Johnson | 52 | $886 |
| Medtronic | 22 | $826 |
| Novartis | 45 | $793 |
| E.r. Squibb & Sons, L.L.C. | 49 | $771 |
| Amgen | 33 | $646 |
| Actelion Pharmaceuticals US, Inc. | 26 | $546 |
| Bayer | 14 | $407 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $349 |
| Boehringer Ingelheim | 15 | $273 |
| Merck | 16 | $253 |
| Amarin Pharma, Inc. | 16 | $251 |
| Shockwave Medical, Inc | 1 | $189 |
| AstraZeneca | 14 | $172 |
| Chiesi USA, Inc. | 9 | $165 |
| Philips North America LLC | 7 | $147 |
| Lexicon Pharmaceuticals, Inc. | 6 | $131 |
| Alnylam Pharmaceuticals Inc. | 4 | $109 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $91 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $71 |
| Impulse Dynamics (USA) Inc. | 2 | $65 |
| Scpharmaceuticals Inc. | 3 | $55 |
| Gilead | 3 | $53 |
| Daiichi Sankyo Inc. | 3 | $49 |
| Heartflow, Inc. | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Atricure, Inc. | 1 | $26 |
| Portola Pharmaceuticals, LLC | 2 | $23 |
| Akcea Therapeutics, Inc. | 1 | $19 |
| Recor Medical Inc | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVOQUE$1,189
- Barostim Neo System$1,034
- Watchman$794
- Impella$490
- ARCALYST$349
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$189
- Adapta$186
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$157
- UPTRAVI$147
- OPSUMIT$147
- Kerendia$125
- TRICLIP$115
How this compares
Too few advanced heart failure and transplant cardiology providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 14 | $362,694 |
| EliquisApixaban | 297 | $332,052 |
| AdempasRiociguat | 16 | $225,403 |
| OpsumitMacitentan | 16 | $207,117 |
| EntrestoSacubitril/Valsartan | 191 | $201,086 |
| CamzyosMavacamten | 23 | $183,764 |
| FarxigaDapagliflozin Propanediol | 163 | $166,528 |
| XareltoRivaroxaban | 46 | $49,833 |
| JardianceEmpagliflozin | 22 | $24,367 |
| Sildenafil Citrate | 25 | $10,335 |
| Repatha SureclickEvolocumab | 18 | $9,478 |
| Midodrine Hcl | 65 | $7,283 |
| Metoprolol Succinate | 319 | $3,860 |
| Amiodarone Hcl | 193 | $3,044 |
| Potassium Chloride | 204 | $2,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $950 | $694,747311 claims |
| BayerAdempas | $407 | $225,40316 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $546 | $207,11716 claims |
| NovartisEntresto | $793 | $201,086191 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $771 | $183,76423 claims |
| AstraZenecaFarxiga | $172 | $166,528163 claims |
| Johnson & JohnsonXarelto | $886 | $49,83346 claims |
| Boehringer IngelheimJardiance | $273 | $24,36722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Utahon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Salt Lake City
- Josef StehlikSalt Lake City$905K
- Kevin FelpelSalt Lake City$8K
- Aditya MehtaSalt Lake City$4K
- Alison BrannSalt Lake City$3K
- Miguel Chavez CavazosOgden$689
- Donya MohebaliSt George$22
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.